Literature DB >> 10090948

Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines.

R Y Liu1, C Fan, R Garcia, R Jove, K S Zuckerman.   

Abstract

The factor-independent Dami/HEL and Meg-01 and factor-dependent Mo7e leukemic cell lines were used as models to investigate JAK/STAT signal transduction pathways in leukemic cell proliferation. Although Dami/HEL and Meg-01 cell proliferation in vitro was independent of and unresponsive to exogenous cytokines including granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), IL-6, thrombopoietin (TPO), and tumor necrosis factor-alpha (TNF-alpha), the growth of Mo7e cells was dependent on hematopoietic growth factors. When these cell lines were cultured in medium without cytokines, a constitutively activated STAT-like DNA-binding factor was detected in nuclear extracts from both Dami/HEL and Meg-01 cells. However, the STAT-like factor was not detectable in untreated Mo7e cells, but was activated transiently in Mo7e cells in response to cytokine treatments. The constitutively activated and cytokine-induced STAT-like DNA-binding factor in these three cell lines was identified as STAT5 by oligonucleotide competition gel mobility assays and by specific anti-STAT antibody gel supershift assays. Constitutive activation of JAK2 also was detected in the factor-independent cell lines, but not in Mo7e cells without cytokine exposure. Meg-01 cells express a p185 BCR/ABL oncogene, which may be responsible for the constitutive activation of STAT5. Dami/HEL cells do not express the BCR/ABL oncogene, but increased constitutive phosphorylation of Raf-1 oncoprotein was detected. In cytokine bioassays using growth factor-dependent Mo7e and TF-1 cells as targets, conditioned media from Dami/HEL and Meg-01 cells did not show stimulatory effects on cell proliferation. Our results indicate that the constitutive activation of JAK2/STAT5 correlates with the factor-independent growth of Dami/HEL and Meg-01 cells. The constitutive activation of JAK2/STAT5 in Dami/HEL cells is triggered by a mechanism other than autocrine cytokines or the BCR/ABL oncoprotein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090948

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

Authors:  Stefan Fröhling; Daniel B Lipka; Sabine Kayser; Claudia Scholl; Richard F Schlenk; Hartmut Döhner; D Gary Gilliland; Ross L Levine; Konstanze Döhner
Journal:  Blood       Date:  2006-02-01       Impact factor: 22.113

2.  A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.

Authors:  Anurima Majumder; Andrew T Magis; Sung O Park; Nicholas C Figueroa; Rebekah Baskin; Annet Kirabo; Robert W Allan; Zhizhuang Joe Zhao; Kirpal S Bisht; György M Keseru; Peter P Sayeski
Journal:  Exp Hematol       Date:  2011-10-20       Impact factor: 3.084

3.  Estrogen promotes megakaryocyte polyploidization via estrogen receptor beta-mediated transcription of GATA1.

Authors:  C Du; Y Xu; K Yang; S Chen; X Wang; S Wang; C Wang; M Shen; F Chen; M Chen; D Zeng; F Li; T Wang; F Wang; J Zhao; G Ai; T Cheng; Y Su; J Wang
Journal:  Leukemia       Date:  2016-10-17       Impact factor: 11.528

4.  Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.

Authors:  Lucy S Hodge; Steven C Ziesmer; Zhi-Zhang Yang; Frank J Secreto; Anne J Novak; Stephen M Ansell
Journal:  Blood       Date:  2013-12-11       Impact factor: 22.113

5.  Protein kinase C δ deficiency enhances megakaryopoiesis and recovery from thrombocytopenia.

Authors:  John C Kostyak; Dheeraj Bhavanasi; Elisabeta Liverani; Steven E McKenzie; Satya P Kunapuli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10-30       Impact factor: 8.311

Review 6.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

7.  Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors.

Authors:  Stefanie Andrea Erika Held; Annkristin Heine; Anne Ruth Kesper; Kathrin Schönberg; Anika Beckers; Dominik Wolf; Peter Brossart
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

8.  JAK2/STAT5/Bcl-xL signalling is essential for erythropoietin-mediated protection against apoptosis induced in PC12 cells by the amyloid β-peptide Aβ25-35.

Authors:  Rong Ma; Jing Hu; Chengfang Huang; Min Wang; Jizhou Xiang; Gang Li
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

9.  The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines.

Authors:  M Baśkiewicz-Masiuk; M Masiuk; B Machaliński
Journal:  Cell Prolif       Date:  2003-10       Impact factor: 6.831

10.  Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells.

Authors:  J Giron-Michel; M Fogli; A Gaggero; S Ferrini; A Caignard; D Brouty-Boye; S Baouz; M-C Le Bousse-Kerdiles; B Peault; M van Dijk; S Bulfone-Paus; D Durali; S Chouaib; B Azzarone
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.